

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- CBER Director Vinay Prasad dared to “say no to drugs”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- As more people are surviving cancer, we must continue funding bold science














